

DIASORIN COMPLETES THE CLIA PANEL OF BACTERIAL GASTROINTESTINAL INFECTIONS, WITH THE LAUNCH OF CAMPYLOBACTER.

May 28th, 2015 - Saluggia (VC) - **DiaSorin** (FTSE Mid Cap: DIA) **launches the LIAISON *Campylobacter*** test for the market outside the US, **completing the bacterial stool-testing panel** that includes Clostridium, EHEC, *H. pylori*.

The LIAISON *Campylobacter* enables laboratories to **reduce the time to result** and allows patients to know immediately whether they are infected by the bacteria.

The LIAISON *Campylobacter* is the 8th test launched as part of our stool-testing offer and is one of the most frequently occurring bacterial agents of gastroenteritis.

The true incidence of gastroenteritis due to *Campylobacter* is poorly known, particularly in emerging markets; studies in high-income countries have estimated the annual incidence at between 4.4 and 9.3 per 1000 population. In the US an estimated 2 million cases of *Campylobacter* enteritis occur annually, accounting for 5-7% of cases of gastroenteritis.

Today, to diagnose *Campylobacter*, laboratories use mainly fecal-culture that takes at least 3 days and requires careful handling of the sample, problems that the new *Campylobacter* will solve.

It is important to diagnose *Campylobacter* in time, considering that 36% of patients with severe *Campylobacter* infections develop inflammatory chronic bowel syndrome (IBS) within 1–2 years. Until now, *Campylobacter* has been considered a lower problematic, but the technology developed by DiaSorin will allow laboratories and therefore doctors to answer in due time with an appropriate treatment in the early stage of the disease.

In a 15 million euros European market with an organic yearly growth of 2-5% DiaSorin will provide an innovative solution, automate, fast, flexible and of high quality.

REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	LIAISON Campylobacter			
Diagnosis	Qualitative determination of Campylobacter in Stool			
Business segment	Immunodiagnosics	✓	Molecular Diagnostics	
Potential market	Stool-testing on a base of minimum of 30 Million euros WW			
Technology	CLIA	✓	Extraction	
	ELISA		Amplification/Detection	
	RIA			
Clinical Area	Infectious Diseases		Infectious Diseases	
	Hepatitis and Retroviruses			
	Oncology & Endocrinology			
	Bone & Mineral			
	Cardiac Markers		Onco-hematology	
	GI Stool Testing	✓		

Carlo Rosa, CEO of DiaSorin Group, commented: *“With the launch of our LIAISON Campylobacter we complete the first and most important part of the Infectious disease stool-testing offer: the bacterial panel. We offer an alternative solution to laboratories that today are using culture, allowing results in less than 1 hour”.*

About DiaSorin

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava

Investor Relations & Corporate Communication Director
 Tel: +39.0161.487988
riccardo.fava@diasorin.it

Margherita Sacerdoti

Investor Relations Specialist
 Tel: +39.0161.487456
margherita.sacerdoti@diasorin.it